[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625393":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":11,"centralContacts":33,"locations":39,"responsibleParty":55,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":11,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":84,"whyStopped":11,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Spanish National Research Council","OTHER_GOV",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Low erythrodiol","ACTIVE_COMPARATOR",null,[13],"Other: Low erythrodiol dose",{"label":15,"type":10,"description":11,"interventionNames":16},"Medium erythrodiol",[17],"Other: Medium erythrodiol dose",{"label":19,"type":10,"description":11,"interventionNames":20},"High erythrodiol",[21],"Other: High erythrodiol dose",[23,27,30],{"type":24,"name":25,"description":25,"armGroupLabels":26,"otherNames":11},"OTHER","Low erythrodiol dose",[9],{"type":24,"name":28,"description":28,"armGroupLabels":29,"otherNames":11},"Medium erythrodiol dose",[15],{"type":24,"name":31,"description":31,"armGroupLabels":32,"otherNames":11},"High erythrodiol dose",[19],[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Javier Perona S. Perona, PhD","CONTACT","34954611550","perona@ig.csic.es",[40],{"facility":41,"status":11,"city":42,"state":11,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Instituto de la Grasa-CSIC","Seville","41013","Spain","ES",{"type":47,"coordinates":48},"Point",[49,50],-5.97317,37.38283,{"lat":50,"lon":49},[53],{"name":35,"role":36,"phone":54,"phoneExt":11,"email":38},"+34954611550",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Javier Sanchez Perona","Scientific Researcher","100625393","phase-2-erythrodiol-in-pomace-olive-oil-as-a-protective-agent-against-atherosclerosis-100625393",false,"NCT07422051","Erythrodiol in Pomace Olive Oil as a Protective Agent Against Atherosclerosis","Inclusion Criteria:\n\n* Adults aged 18 to 40 years.\n* Male or female volunteers.\n* Healthy individuals with no diagnosed diseases.\n* Normal-weight participants with a Body Mass Index (BMI) between 18.5 and 24.9 kg\u002Fm².\n* Ability to provide voluntary informed consent.\n* Willingness to comply with all study procedures.\n* Availability to participate in the two-phase selection process, including initial screening and subsequent laboratory tests.\n\nExclusion Criteria:\n\n* Presence of any type of disease, including digestive, metabolic, endocrine, infectious, neoplastic conditions, or associated allergies and food intolerances.\n* Current use of any medication, except hormonal contraceptives.\n* Pregnant or breastfeeding women.\n* Participation in a clinical trial with an investigational product within the last 60 days, or current enrolment in a clinical trial.\n* Any physical or intellectual limitation that, in the opinion of the investigator, could impede following or completing the study protocol.",true,"ALL","18 Years","40 Years",{"count":70,"type":71},22,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","The goal of this postprandial clinical trial is to learn whether erythrodiol, a triterpene naturally present in pomace olive oil, can modulate the cell foam formation, ine of the first steps in atherosclerosis. The main questions it aims to answer are:\n\nIs erythrodiol bioavailable in humans when administered as pomace olive oil? Does acute erythrodiol intake reduce postprandial triglyceride excursions after a high-fat meal? Does erythrodiol reduce the intake of postprandial triglyceride-rich lipoproteins by macrophages?\n\nResearchers will compare participants receiving test meals enriched with different concentrations of erythrodiol (low, medium, high) to see if the intervention leads to improved postprandial metabolic and vascular responses.\n\nParticipants will:\n\nAttend the research facility after an overnight fast. Consume a high-fat test meal enriched with a different doses of erythrodiol\n\nUndergo serial postprandial assessments over several hours, including:\n\nBlood sampling for lipids, glucose, inflammatory markers, and oxidative stress biomarkers Monitoring of subjective tolerability and adverse events",[77],"Atherosclerosis Cardiovascular Disease",[79,80,81,82,83],"Randomized postprandial crossover trial","Erythrodiol","Pomace olive oil","Atherosclerosis","Macrophages","NOT_YET_RECRUITING","2026-02-18",{"date":87,"type":88},"2026-02-19","ACTUAL",{"date":90,"type":71},"2026-02-21",{"date":92,"type":71},"2026-12-30",{"name":5,"class":6},1]